Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis

Abstract The precise clinicopathologic significance of myeloid differentiation primary response gene (MYD88) L265P mutation in diffuse large B-cell lymphomas (DLBCLs) remains elusive. To investigate the frequency and clinicopathologic significance of the MYD88 L265P mutation in DLBCLs, we conducted...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ju-Han Lee, Hoiseon Jeong, Jung-Woo Choi, HwaEun Oh, Young-Sik Kim
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/accd3cebac4a4ace9ddfdf9723f0b725
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:accd3cebac4a4ace9ddfdf9723f0b725
record_format	dspace
spelling	oai:doaj.org-article:accd3cebac4a4ace9ddfdf9723f0b7252021-12-02T12:30:37ZClinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis10.1038/s41598-017-01998-52045-2322https://doaj.org/article/accd3cebac4a4ace9ddfdf9723f0b7252017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-01998-5https://doaj.org/toc/2045-2322Abstract The precise clinicopathologic significance of myeloid differentiation primary response gene (MYD88) L265P mutation in diffuse large B-cell lymphomas (DLBCLs) remains elusive. To investigate the frequency and clinicopathologic significance of the MYD88 L265P mutation in DLBCLs, we conducted a meta-analysis of 40 published studies on 2736 DLBCL patients. We collected relevant published research findings identified using the PubMed and Embase databases. The effect sizes of outcome parameters were calculated using a random-effects model. In this meta-analysis, the MYD88 L265P mutation in DLBCL showed a significant difference according to tumor sites. The overall incidence of the MYD88 L265P mutation in DLBCLs, excluding the central nervous system and testicular DLBCLs, was 16.5%. Notably, the MYD88 L265P mutation rates of CNS and testicular DLBCL patients were 60% and 77%, respectively. Interestingly, the MYD88 L265P mutation was more frequently detected in activated B-cell-like (ABC) or non-germinal center B-cell-like (GCB) than GCB subtype (OR = 3.414, p < 0.001). The MYD88 L265P mutation was significantly associated with old age and poor overall survival, but not with sex and clinical stage. This pooled analysis demonstrates that the MYD88 L265P mutation is significantly associated with the tumor sites and molecular subtypes in DLBCL patients.Ju-Han LeeHoiseon JeongJung-Woo ChoiHwaEun OhYoung-Sik KimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ju-Han Lee Hoiseon Jeong Jung-Woo Choi HwaEun Oh Young-Sik Kim Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
description	Abstract The precise clinicopathologic significance of myeloid differentiation primary response gene (MYD88) L265P mutation in diffuse large B-cell lymphomas (DLBCLs) remains elusive. To investigate the frequency and clinicopathologic significance of the MYD88 L265P mutation in DLBCLs, we conducted a meta-analysis of 40 published studies on 2736 DLBCL patients. We collected relevant published research findings identified using the PubMed and Embase databases. The effect sizes of outcome parameters were calculated using a random-effects model. In this meta-analysis, the MYD88 L265P mutation in DLBCL showed a significant difference according to tumor sites. The overall incidence of the MYD88 L265P mutation in DLBCLs, excluding the central nervous system and testicular DLBCLs, was 16.5%. Notably, the MYD88 L265P mutation rates of CNS and testicular DLBCL patients were 60% and 77%, respectively. Interestingly, the MYD88 L265P mutation was more frequently detected in activated B-cell-like (ABC) or non-germinal center B-cell-like (GCB) than GCB subtype (OR = 3.414, p < 0.001). The MYD88 L265P mutation was significantly associated with old age and poor overall survival, but not with sex and clinical stage. This pooled analysis demonstrates that the MYD88 L265P mutation is significantly associated with the tumor sites and molecular subtypes in DLBCL patients.
format	article
author	Ju-Han Lee Hoiseon Jeong Jung-Woo Choi HwaEun Oh Young-Sik Kim
author_facet	Ju-Han Lee Hoiseon Jeong Jung-Woo Choi HwaEun Oh Young-Sik Kim
author_sort	Ju-Han Lee
title	Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
title_short	Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
title_full	Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
title_fullStr	Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
title_full_unstemmed	Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
title_sort	clinicopathologic significance of myd88 l265p mutation in diffuse large b-cell lymphoma: a meta-analysis
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/accd3cebac4a4ace9ddfdf9723f0b725
work_keys_str_mv	AT juhanlee clinicopathologicsignificanceofmyd88l265pmutationindiffuselargebcelllymphomaametaanalysis AT hoiseonjeong clinicopathologicsignificanceofmyd88l265pmutationindiffuselargebcelllymphomaametaanalysis AT jungwoochoi clinicopathologicsignificanceofmyd88l265pmutationindiffuselargebcelllymphomaametaanalysis AT hwaeunoh clinicopathologicsignificanceofmyd88l265pmutationindiffuselargebcelllymphomaametaanalysis AT youngsikkim clinicopathologicsignificanceofmyd88l265pmutationindiffuselargebcelllymphomaametaanalysis
_version_	1718394354776670208

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis

Ejemplares similares